



## **Brian J. Druker, M.D.**

Dr. Brian Druker is director of the OHSU Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, and a Howard Hughes Medical Institute Investigator. As director of the OHSU Knight Cancer Institute, Dr. Druker is committed to making Oregon's cancer death rate the lowest in the nation.

Dr. Druker earned his medical degree at the University of California, San Diego, performed his internship and residency at Washington University's Barnes Hospital, and obtained medical oncology training at Harvard's Dana-Farber Cancer Institute. He joined OHSU in 1993.

Dr. Druker led the development of Gleevec, a targeted cancer pill that has revolutionized cancer research and treatment. The drug works by targeting and turning off specific proteins in cancer cells that drive the growth of tumors while leaving healthy cells alone. Initially approved to treat chronic myeloid leukemia, Gleevec is now FDA-approved to treat six other cancers.

Dr. Druker has received numerous honors for his pioneering work, including top awards from The Leukemia and Lymphoma Society, the Lance Armstrong Foundation and the American Cancer Society. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, the American Association of Physicians in 2006, and the National Academy of Sciences in 2007.